Key Takeaways
- Revenue grew 24% YoY, but US syringe shortages capped the quarter: Core markets grew only 8% YoY as component shortages prevented exports, forcing costly airlifts that compressed gross margins.
- EBITDA margin fell to 35% from 40% YoY: The squeeze came from logistics costs, power and fuel inflation, and one-time acquisition fees, partially offset by operating leverage. Management targets a 35–37% band internally.
- The launch pipeline is loaded for H2 FY23: ~24–25 molecules worth about $3 billion in innovator sales are planned over the next three quarters, with a larger LOE wave expected in the second half.
- Vaccine facility repurposing to biosimilars is accelerating: One line is being converted for biosimilar CDMO work with partner discussions underway, pulling forward the timeline versus waiting for the vaccine opportunity to expire.
- What to watch next quarter: Whether syringe supply normalizes as promised, the pace of Enoxaparin partner volume ramp-up from June–July, and any M&A announcement in the “next few months.”
US Business: Syringe Shortages and the Launch Bridge
- Syringe shortages choked Q4 exports: Component shortages across vials, stoppers, tubing and filters, diverted to vaccine manufacturing, prevented follow-up batch supply and pushed some planned launches to the end of this quarter. Lead times have worsened.
- Airlifting components protected revenue but hurt margins: The company flew in alternate-source syringes to meet demand, increasing logistics costs. Domestic and other markets got priority for those syringes, which also lifted third-party sales in India.
- Pricing held firm despite shortages: Prices did not rise but at least stopped declining. Volumes for certain products increased unexpectedly because competitors exited, a dynamic management did not anticipate.
- The launch bridge is substantial: Over the next three quarters, launches worth about $3 billion in innovator sales are planned across ~24–25 molecules. A larger LOE year is expected in H2 FY23, with higher new launch contribution and profit share.
- US growth may decelerate on a high base: Management targets at least 10% company-level growth with 10–11% from new products, acknowledging percentage growth may not match prior years because the base is now large.
Srinivas Sadu: “I have not seen a case where the price have gone up in recent times, it always in spite of the shortages, still the prices are kind of normal, but at least it will not go down for sure, but the volumes are increasing for certain products, which we never thought it will increase because of the shortages.”
Enoxaparin: Partner Transition and Margin Ambition
- Partner dynamics are shifting: One partner lost market share and held off purchasing due to low margins and volumes. A GPO contract with another partner is now ramping up, with volumes expected to entirely shift to Gland by June–July.
- Supply was constrained by the same syringe shortages: Ramp-up was limited by component availability; management expects improvement from June–July as syringe supply normalizes.
- Margin improvement hinges on Heparin sourcing: The priority is to increase margins by sourcing crude Heparin from non-China sources, which are cheaper than China today, and getting those sources approved for the US ANDA. Geographic expansion beyond the US waits on securing that supply chain.
- Geographic expansion is selective: Management is looking at several markets beyond the US where competition is lower, but is avoiding Europe due to price pressure and registration complexity. China is a key market but has backward-integrated local players.
- Global market share is small: Per management’s “wild guess,” Gland holds roughly 10% of the global Enoxaparin market by volume, with Europe and China representing the bulk of the remaining opportunity.
Margins: The 35–37% Floor Under Pressure
- Q4 EBITDA margin fell 500 bps YoY to 35%: The decline was driven by higher logistics costs from airlifting components, a 30% increase in power and fuel costs, and one-time legal and professional fees of ~₹5.5 crore for ongoing acquisition evaluation.
- Vizag ran on diesel for 40–45 days: Power supply issues at the Vizag plants forced diesel generator use, significantly increasing power, diesel and utilities costs on an annual basis.
- Staff costs rose on multiple fronts: Additional lines coming online required recruitment, annual increments took effect in January, and incentive payouts hit in the quarter. Some incentive components will not repeat every quarter.
- Gross margin varies with contract manufacturing mix: Quarters with a larger contract manufacturing portion show better gross margins, so the metric is not a reliable standalone indicator. Management focuses on EBITDA margin internally.
- Internal target is 35–37% EBITDA, ~25% PAT: Management declined to give forward guidance but stated this is the band it always looks at internally. Operating leverage from higher volumes is the primary offset to cost pressures.
Srinivas Sadu: “Internally, like I said, gross margin is not a criteria for us, but at the EBITDA margin level, we always look at 35%-37% levels of EBITDA margins and at the PAT level around 25%. That is how we internally always look towards that.”
India and ROW: The Growth Engines That Delivered
- India grew 137% YoY in Q4: Volume growth of existing products drove the surge, with key launches including Caspofungin Acetate and Enoxaparin Sodium multidose cartridge with a pen device. Third-party sales also rose as alternate-source syringes were directed to the domestic market.
- ROW markets grew 32% YoY in Q4: Enoxaparin Sodium was a key contributor. For the full year, ROW grew 55%.
- Indian partners are exporting more to the US: Piramal was added as a new partner, and Sun Pharma is selling more products in the US. Profitability on this business is similar to exporting to a US partner. Management expects the share of Indian partners to increase as more products go to more players with US front-ends.
- Quality standards will not be diluted for ROW: Despite margin pressure in ROW markets, management will keep quality standards common across all sites to avoid confusion and maintain corporate quality systems.
Srinivas Sadu: “There was debate always on this, but I think we want to keep the quality standard across the sites similar, we don't want to dilute that because at a long run that helps because from the corporate quality perspective, we want to have a common quality systems across sites, so there is no confusion and different qualities at different sites.”
Complex Pipeline and Capacity Build-Out
- Complex portfolio filings began: Three hormonal filings and one complex peptide filing were made during FY22. R&D revenue expense rose 61% YoY, and DMF filings accelerated to 11 in the year versus a historical 5–6.
- Penem portfolio commercialized: Ertapenem and Meropenem were launched during the year. Penem capacity is currently unable to meet demand, and investment is underway to expand it.
- Bags capacity is 100% utilized: Planned investment will expand capacity.
- API backward integration deepened: Internal API share rose from ~23% to ~34% of revenue. Further expansion is expected to eliminate supplier risk and improve gross margins, though the impact is not quantified.
- CAPEX plan: ₹300 crores in FY23, ₹250 crores the year after, covering a complex injectables suite at Pashamylaram, warehouse expansion, bags lines, a lyophilizer addition in Penem, and API capacity expansion for Enoxaparin.
- R&D spend will rise in absolute terms: As complex injectables become a larger share of the portfolio, R&D spend should settle at 4–5% of revenue. A new R&D facility was commissioned during FY22.
Capital Allocation: M&A and the Biosimilar Pivot
- M&A focus is on complex injectables first, then fermentation API: Management is actively working on a couple of opportunities and believes valuations now have “some sanity” after being “all over the place” last year. A deal is hoped for in the next few months.
- Vaccine facility repurposing is accelerating the biosimilar timeline: One line is being converted for biosimilar CDMO work, with partner discussions ongoing and site visits already completed. Preliminary work is expected to start soon. The original plan was to wait for the vaccine opportunity to end by late 2022 and start in Q1 2023; repurposing pulls that forward.
- No write-off of vaccine inventory yet: Bags and other materials can be used for biosimilar production. Repurposing does not involve much expense since no commercial production was done.
- A second vaccine line is being kept on standby: One line will be retained for the vaccine opportunity for a few more months while the other moves to biosimilars.
- China biosimilar work is ongoing: The company will do some work as a subsidiary of the parent and is also collaborating with external companies and internal subsidiaries. NMPA inspection dates are pending because China remains shut down.
Srinivas Sadu: “Last year is more like the valuations were all over the place. Now, there is some sanity around the valuation. So, we are working actively on couple of things. So, hopefully we should give something in next few months.”
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Syringe shortage resolution | Catch up on backlog; still short 0.3–0.4 crore syringes this quarter | Next quarter (Q1/Q2 FY23) |
| Enoxaparin partner volume shift | Partner volumes expected to entirely shift to Gland | June–July 2022 |
| US launch cadence | ~24–25 molecules worth ~$3 bn innovator sales | Next 3 quarters |
| CAPEX spend | ₹300 crores | FY23 |
| CAPEX spend | ₹250 crores | FY24 |
| R&D spend ratio | 4–5% of revenue as complex injectables share rises | Ongoing |
| M&A announcement | Actively working on a couple of things; valuations now saner | “Next few months” |
| Vaccine facility repurposing | One line converting to biosimilars; preliminary work starting soon | Discussions underway, visits done |
| Internal margin target | 35–37% EBITDA, ~25% PAT | Ongoing internal benchmark |
| Company-level growth target | At least 10%, with 10–11% from new products | FY23 |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue | ₹1,103 crore, +24% YoY |
| Full-year FY22 revenue | ₹4,400.7 crore, +27% YoY |
| PAT | ₹285.9 crore, +10% YoY |
| Full-year FY22 PAT | ₹1,211.7 crore, +22% YoY |
| PAT margin | 24%, vs 26% for full year FY22 |
| EBITDA | ₹413.6 crore, +10% YoY |
| EBITDA margin | 35%, vs 40% in Q4 FY21 |
| Full-year FY22 EBITDA margin | 37%, vs 40% in FY21 |
| Core markets revenue share | 64% of Q4 revenue, vs 74% in Q4 FY21; +8% YoY |
| Rest of World markets revenue share | 17% of Q4 revenue, +32% YoY |
| India market revenue share | 18% of Q4 revenue, +137% YoY |
| R&D revenue expense | ₹44.3 crore, 4% of revenue, vs ₹30.2 crore in Q4 FY21 |
| Full-year FY22 R&D revenue expense | ₹193.2 crore, +61% YoY; 4.4% of revenue excluding capex R&D |
| Cash flow from operations (FY22) | ₹790.8 crore |
| CAPEX incurred (FY22) | ₹522.1 crore |
| Cash conversion cycle (FY22) | 187 days, improved from 192 days in FY21 |
| ROCE on ex-cash basis | 33% as on March 31, 2022 |
| ANDA filings in the US (cumulative) | 311 as on March 31, 2022 |
| Product registrations globally (cumulative) | 1,557 as on March 31, 2022 |
| Internal API share of revenue | 33–34%, up from 23–24% a year ago |
| Profit share contribution | ~10% of revenue |
| Effective tax rate | ~25% |
| CAPEX plan for FY23 | ₹300 crore |